Medtronic’s Evolut valve reduces dysfunction, improves quality of life in women with severe aortic stenos

May 20 2024Medtronic Medtronic, the global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement , the SMall Annuli Randomized To Evolut or SAPIEN Trial, looking exclusively at women. The findings showed the Evolut self-expanding valve was associated with significantly less bioprosthetic valve dysfunction and improved quality of life for women with symptomatic severe aortic stenosis .

Results demonstrated the primary clinical endpoint for composite of death, disabling stroke, or heart failure rehospitalization was similar amongst women with AS and small annulus randomized to balloon-expandable valve or SEV at one year. However, , compared to a balloon-expandable valve, the Evolut SEV was associated with significantly less BVD , less prosthesis-patient mismatch , less mild or greater total aortic regurgitation , and improved quality of life in women with AS and small annulus.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

New data reveals optimal timing for percutaneous coronary intervention in TAVR patientsNew data reveals that percutaneous coronary intervention (PCI) can be safely performed before, during, or after transcatheter aortic valve replacement (TAVR) for patients with stable coronary artery disease (CAD).
Source: NewsMedical - 🏆 19. / 71 Read more »

Large registry data demonstrate PCI for stable CAD can be safely performed before, during or after TAVRNew data reveal that percutaneous coronary intervention (PCI) can be safely performed before, during, or after transcatheter aortic valve replacement (TAVR) for patients with stable coronary artery disease (CAD).
Source: medical_xpress - 🏆 101. / 51 Read more »